- Evaluate predictive value of B cell/TLS signatures identified through RNA-seq for patient survival following immune checkpoint inhibitor (ICI) versu other therapies in solid tumors.
- Characterize the genomic landscape (mutational status, copy number variations) of tumors enriched with B cell/TLS signatures compared to those without.
- Compare genomic profiles (mutational status, copy number variations) between responders and non-responders to ICI therapy in B cell/TLS signature-enriched tumors.
Publications
Atlas of Tertiary Lymphoid Structures in Solid Tumors: Genomic Features and Prediction of Response to Immunotherapy
– Caris Life Sciences